Related Experiment Video
Updated: May 22, 2026
23:33
The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
Published on: February 28, 2012
Anticoagulation strategies in atrial fibrillation
Arthur R Menezes1, Surya Artham, Carl J Lavie
1Department of Cardiovascular Diseases, The University of Queensland School of Medicine, New Orleans, LA, USA.
Reviews in Cardiovascular Medicine
|May 9, 2012
Summary
Atrial fibrillation (AF) increases stroke risk, especially in older adults. Newer anticoagulants offer alternatives to vitamin K antagonists for stroke prevention in AF patients.
Area of Science:
- Cardiology
- Pharmacology
- Geriatrics
Background:
- Atrial fibrillation (AF) is a significant risk factor for stroke and systemic embolization.
- AF prevalence is increasing, particularly in the elderly population.
- Current treatments like vitamin K antagonists have limitations for many patients.
Purpose of the Study:
- To examine and compare newer therapeutic agents for stroke prevention in AF.
- To provide an overview of established antithrombotic therapies.
- To discuss anticoagulation in cardioversion for AF patients.
Main Methods:
- Review of FDA-approved and investigational anticoagulants.
- Comparison of novel oral anticoagulants (NOACs) with traditional therapies.
- Analysis of anticoagulation strategies in AF management.
Main Results:
- Newer agents offer alternatives to vitamin K antagonists.
- Established antithrombotic therapies remain relevant.
- Anticoagulation plays a crucial role in AF cardioversion.
Conclusions:
- Novel anticoagulants represent a significant advancement in AF stroke prevention.
- A comprehensive understanding of all antithrombotic options is essential.
- Individualized treatment strategies are necessary for optimal patient outcomes.
Related Concept Videos
01:29Venous Thrombosis III: Interprofessional Care
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
01:29Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care
Diagnosing Pulmonary EmbolismDiagnosing pulmonary embolism (PE) involves clinical assessment and advanced imaging tests. The preferred diagnostic tool is the spiral (helical) CT scan or CT angiography (CTA), which uses intravenous contrast media to visualize the pulmonary vasculature and identify emboli.A ventilation-perfusion (V/Q) scan is an alternative for patients unable to receive contrast media. This scan includes both perfusion and ventilation scanning. Perfusion scanning involves...
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
01:25Dysrhythmias VI: Management of Dysrhythmias
Dysrhythmia management involves a multifaceted approach, incorporating pharmacological treatments, medical procedures, surgical interventions, lifestyle modifications, and patient education.Pharmacological ManagementAntiarrhythmic Drugs:Class I (Sodium Channel Blockers): This class includes quinidine and procainamide, which reduce the speed of impulse conduction in the heart, stabilize the cardiac membrane, and control arrhythmias. Quinidine and procainamide are Class IA agents that prolong the...